Zak comment10 Aug 2023 09:09
Cizzle Biotechnology (CIZ), the UK based diagnostics developer, announced an expansion of its current research programme with the University of York to develop its CIZ1B biomarker technology for early stage cancer diagnosis, and other potential applications in cancer therapy. The company said the University of York has been the home of the company’s research and development from its inception. Under the expert and insightful leadership of Professor Coverley, the laboratory team have made excellent progress in developing its test for the CIZ1B Biomarker to be used for detecting lung cancer at its earliest stage.
Comment: It was interesting to see shares of CIZ stir in a positive way earlier this week, as presumably clairvoyant investors successfully anticipated today’s positive news. Hopefully soon, the seller in the stock who has been irritating persistent will finally disappear into the sunset soon.